JARDIANCE ®
PROTECTION
# 1
#
Type 2 diabetes : indicated to prevent CV death * & for glycaemic control . 1 Heart failure : indicated to treat symptomatic HF independent of LVEF . † 1 Chronic kidney disease : indicated to reduce the risk of kidney disease progression . ‡ 1
* T2D & eCVD indication : in adult patients with T2D and established CV disease ( CAD , PAD , MI or stroke ) on top of SOC . 1 † In adults for the treatment of symptomatic HF independent of LVEF , as an adjunct to SOC therapy . 1 ^JARDIANCE ® HFpEF TGA approved in 13 December 2022 . ‡ CKD Stages 2 and 3A with uACR ≥30 mg / g , or CKD Stages 3B , 4 and 5 irrespective of uACR . 1 Due to limited experience , it is not recommended to initiate treatment with JARDIANCE ® in patients with an eGFR < 20 mL / min / 1.73 m 2 . 1
PBS Information : JARDIANCE ® : Authority Required ( STREAMLINED ). Type 2 Diabetes , Chronic Heart Failure and Chronic Kidney Disease . Refer to PBS Schedule for full Authority Required Information .
BEFORE PRESCRIBING , PLEASE REVIEW THE FULL PRODUCT INFORMATION AVAILABLE FROM BOEHRINGER INGELHEIM AT WWW . BOEHRINGER-INGELHEIM . COM . AU / PI OR BY SCANNING THE QR CODE .
Use of this medicinal product in paediatric patients aged 10 to 17 years with type 2 diabetes mellitus is subject to additional monitoring in Australia . This will allow quick identification of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems